Insight Molecular Diagnostics Inc (IMDX) Stock Price, Quote & News

Company Profile

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The compa...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 949 409 7600

Website: imdxinc.com

Address:

2 International Plaza Dr., Suite 510, Nashville, United States

JohnPDaly Sep. 11 at 4:50 PM

$IMDX Here I am alone in the stock.

1 · Reply

RobertoSalazar1998 Sep. 11 at 4:02 PM

$IMDX nice start

0 · Reply

JohnPDaly Sep. 11 at 2:51 PM

$MDWD $LCTX $IMDX bought more and a little Bitty as well !

0 · Reply

cache1b Sep. 11 at 7:44 AM

$IMDX http://stocktwits.com/cache1b/message/628264981 @RUNNINWILD Thanks.... @LefDeppard

0 · Reply

cache1b Sep. 11 at 7:42 AM

$IMDX @JohnPDaly First post, ass dial Got Feedback, too funny... Thanks! Looked at chart, when the universe knocks, you got to open the door. Yah. I see it, $4 next couple of months, $10 real quick right after. Nice chart, would like more volume.... Tty on upmove/volume.

0 · Reply

NVDAMillionaire Sep. 11 at 6:28 AM

$IMDX Excellent article that nails exactly where IMDX stands right now. So if you want to update your IMDX knowledge or get acquainted with IMDX, this is a must read. https://beyondspx.com/quote/IMDX/analysis/insight-molecular-diagnostics-unlocking-transplant-value-with-a-kitted-revolution-nasdaq-imdx

0 · Reply

cache1b Sep. 10 at 7:09 PM

$IMDX 0,¹22²33³²⅘⁵555⁵5556677⅞)}++⁶(<{>)>a lot 8?⁸77-553317777111

2 · Reply

jackedmund99 Sep. 10 at 6:02 PM

$IMDX hopefully the market is waking up to the real promises that this company has- market cap of 500 mill now is not unreasonable

1 · Reply

JohnPDaly Sep. 10 at 4:26 PM

$IMDX

0 · Reply

JohnPDaly Sep. 10 at 4:07 PM

$IMDX 👀

0 · Reply

Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database

Sep 8, 2025, 7:00 AM EDT - 3 days ago

IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants

Aug 26, 2025, 4:05 PM EDT - 16 days ago

iMDx to Participate in NYC Investment Conferences September 8 - 11

Aug 11, 2025, 4:05 PM EDT - 4 weeks ago

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

Aug 4, 2025, 4:05 PM EDT - 5 weeks ago

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

Jul 30, 2025, 4:05 PM EDT - 6 weeks ago

IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients

Jul 28, 2025, 4:05 PM EDT - 6 weeks ago

iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025

Jun 23, 2025, 4:05 PM EDT - 2 months ago

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing

Jun 17, 2025, 7:00 AM EDT - 3 months ago

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

May 19, 2025, 4:05 PM EDT - 4 months ago

Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

May 12, 2025, 11:32 PM EDT - 4 months ago

OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:05 PM EDT - 4 months ago

Oncocyte Reports Q1 2025 Results and Business Progress

May 7, 2025, 4:10 PM EDT - 4 months ago

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Apr 30, 2025, 8:30 AM EDT - 4 months ago

Oncocyte Provides Positive Update on Clinical Trial Progress

Apr 29, 2025, 8:30 AM EDT - 4 months ago

Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

Mar 24, 2025, 6:53 PM EDT - 6 months ago

OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 4:05 PM EDT - 6 months ago

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Feb 11, 2025, 8:30 AM EST - 7 months ago

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 8, 2025, 8:30 AM EST - 8 months ago

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Jan 6, 2025, 4:05 PM EST - 8 months ago

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Nov 12, 2024, 8:52 PM EST - 10 months ago

OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:45 PM EST - 11 months ago

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Oct 16, 2024, 4:15 PM EDT - 11 months ago

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

Aug 10, 2024, 1:00 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

Jun 24, 2024, 12:41 PM EDT - 1 year ago

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

May 30, 2024, 4:47 PM EDT - 1 year ago

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

May 15, 2024, 10:15 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript

May 15, 2024, 4:05 PM EDT - 1 year ago

Oncocyte Reports First Quarter 2024 Financial Results

Apr 12, 2024, 1:44 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript

Apr 12, 2024, 6:00 AM EDT - 1 year ago

Oncocyte Reports Full Year 2023 Financial Results

Apr 9, 2024, 4:05 PM EDT - 1 year ago

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

Nov 9, 2023, 9:36 AM EST - 2 years ago

OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript

Aug 10, 2023, 12:06 PM EDT - 2 years ago

OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript

Jul 25, 2023, 9:08 AM EDT - 2 years ago

VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

Jul 24, 2023, 1:35 PM EDT - 2 years ago

Oncocyte Announces 1-For-20 Reverse Stock Split

Jun 27, 2023, 8:30 AM EDT - 2 years ago

Oncocyte Begins Manufacturing Transplant Blood Test

Jun 1, 2023, 4:15 PM EDT - 2 years ago

Oncocyte Corporation to Present at the LD Micro Invitational XIII

May 11, 2023, 8:00 AM EDT - 2 years ago

Oncocyte Reports First Quarter 2023 Financial Results

Apr 27, 2023, 4:59 PM EDT - 2 years ago

Oncocyte To Announce First Quarter 2023 Financial Results

Apr 18, 2023, 8:45 AM EDT - 2 years ago

Oncocyte Presents New Data at AACR

Apr 12, 2023, 4:15 PM EDT - 2 years ago

Oncocyte Announces Reduction in Force

Apr 7, 2023, 8:24 AM EDT - 2 years ago

Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer

Apr 3, 2023, 11:40 AM EDT - 2 years ago

OncoCyte Corporation (OCX) Q4 2022 Earnings Call Transcript

Mar 31, 2023, 5:00 PM EDT - 2 years ago

Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K

Mar 29, 2023, 4:01 PM EDT - 2 years ago

Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call

Mar 15, 2023, 4:01 PM EDT - 2 years ago

Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results

Mar 2, 2023, 9:00 AM EST - 2 years ago

Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer

Feb 22, 2023, 8:00 AM EST - 2 years ago

Oncocyte Completes Razor Genomics Transaction

Dec 16, 2022, 8:19 AM EST - 2 years ago

Oncocyte cuts 40% of staff

Dec 16, 2022, 8:00 AM EST - 2 years ago

Oncocyte Announces Initiatives to Focus Corporate Strategy

JohnPDaly Sep. 11 at 4:50 PM

$IMDX Here I am alone in the stock.

1 · Reply

RobertoSalazar1998 Sep. 11 at 4:02 PM

$IMDX nice start

0 · Reply

JohnPDaly Sep. 11 at 2:51 PM

$MDWD $LCTX $IMDX bought more and a little Bitty as well !

0 · Reply

cache1b Sep. 11 at 7:44 AM

$IMDX http://stocktwits.com/cache1b/message/628264981 @RUNNINWILD Thanks.... @LefDeppard

0 · Reply

cache1b Sep. 11 at 7:42 AM

0 · Reply

NVDAMillionaire Sep. 11 at 6:28 AM

0 · Reply

cache1b Sep. 10 at 7:09 PM

$IMDX 0,¹22²33³²⅘⁵555⁵5556677⅞)}++⁶(<{>)>a lot 8?⁸77-553317777111

2 · Reply

jackedmund99 Sep. 10 at 6:02 PM

$IMDX hopefully the market is waking up to the real promises that this company has- market cap of 500 mill now is not unreasonable

1 · Reply

JohnPDaly Sep. 10 at 4:26 PM

$IMDX

0 · Reply

JohnPDaly Sep. 10 at 4:07 PM

$IMDX 👀

0 · Reply

JohnPDaly Sep. 9 at 8:54 PM

$IMDX once again, as the only one here, I want to congratulate myself. Well, done.

0 · Reply

BioTuesdays Sep. 8 at 4:21 PM

$IMDX has announced a positive strategic update and novel registry to gather real-world data on patient experiences and outcomes concerning its flagship kidney transplant rejection assay. https://biotuesdays.com/2025/09/08/imdx-launches-novel-registry-database-reports-positive-strategic-update/

1 · Reply

JohnPDaly Sep. 8 at 11:29 AM

IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants – Insight Molecular Diagnostics Inc. $IMDX https://investors.imdxinc.com/news-releases/2025/09-08-2025-120207162

0 · Reply

AlphaProspector Aug. 27 at 9:42 AM

$IMDX volatile swings, risk management key here.

0 · Reply

RUNNINWILD Aug. 26 at 3:49 PM

$IMDX https://stocks.apple.com/ADl9wLbtGQWeGyrCpnhzRCw

0 · Reply

JohnPDaly Aug. 20 at 1:46 PM

$IMDX

0 · Reply

prismmarketview Aug. 19 at 2:42 PM

(NASDAQ: $IMDX) Insight Molecular Diagnostics is turning heads with GraftAssureDx, its in-house dd-cfDNA transplant test delivering same-day, in-hospital results vs. 5–7 day delays. With a $1B+ market opportunity and strong KOL support, analysts see game-changing potential—Needham reaffirmed its Buy & $4.25 PT. https://prismmarketview.com/insight-molecular-diagnostics-imdx-kol-event-bullish-on-graftassuredx-potential/

1 · Reply

JarvisFlow Aug. 18 at 10:00 AM

Needham has updated their rating for Insight Molecular ( $IMDX ) to Buy with a price target of 4.25.

0 · Reply

JohnPDaly Aug. 15 at 9:11 PM

$IMDX always bet on better cheaper faster.

0 · Reply

RUNNINWILD Aug. 12 at 4:30 PM

$IMDX doing a little pecking DCA today

0 · Reply

prismmarketview Aug. 12 at 2:49 PM

Nasdaq: $IMDX Insight Molecular Diagnostics @iMDxInc posted Q2 revenue of $518K and reiterated plans to submit its GraftAssureDx transplant monitoring assay to the FDA by year-end, targeting a mid-2026 launch. Clinical trials are enrolling top transplant centers, and new data highlights the potential for broader dd-cfDNA applications across multiple organ types https://prismmarketview.com/insight-molecular-diagnostics-reports-q2-results-maintains-timeline-for-graftassuredx-fda-submission/

0 · Reply

jackedmund99 Aug. 11 at 9:21 PM

$IMDX after hour trades are bullshit nothing crap

0 · Reply

Market Cap	85.86M
Revenue (ttm)	1.88M
Net Income (ttm)	-60.66M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,226.60%
Debt to Equity Ratio	0.00

Volume	83,200
Avg Vol	38,106
Day's Range	N/A - N/A
Shares Out	28.62M
Stochastic %K	88%
Beta	1.10
Analysts	Sell
Price Target	$5.42